richvintage / iStockphoto.com

7 June 2018Americas

BIO 2018: Kraft president talks biotech and sport

Private capital must finance the life sciences industry in the US otherwise the country will lose its advantage in the life sciences field, claimed Jonathan Kraft, president of The Kraft Group.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO 2018: Anything is possible, says first-ever human gene therapy patient

6 June 2018 “I have a message for all of you searching for a treatment and a cure in your lifetime; I hope you can look at my story and know that anything is possible,” said Ashanti DeSilva to attendees at the 2018 BIO International Convention.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More on this story

BIO 2018: Anything is possible, says first-ever human gene therapy patient

6 June 2018 “I have a message for all of you searching for a treatment and a cure in your lifetime; I hope you can look at my story and know that anything is possible,” said Ashanti DeSilva to attendees at the 2018 BIO International Convention.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More on this story

BIO 2018: Anything is possible, says first-ever human gene therapy patient

6 June 2018 “I have a message for all of you searching for a treatment and a cure in your lifetime; I hope you can look at my story and know that anything is possible,” said Ashanti DeSilva to attendees at the 2018 BIO International Convention.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool